The development of anti-nuclear antibodies (ANA) has been found in 10 to 30% of patients under treatment with<unk> . A systemic disease with arthralgic pain and myalgias has been observed in 1%. A lupus erythematosus-like syndrome with skin rash and multiforme organ involvement is even less frequent. The incidence of both ANA and symptomatic disease under<unk>  is higher than under propranolol. Female patients are more likely to develop these symptoms than male patients. Some few cases of hepatotoxicity with increased liver enzymes (ALT, AST) have been seen. Altogether, 5 to 6% of all patients treated have to discontinue<unk>  due to intolerable side effects. When possible, the treatment should be discontinued gradually in order to avoid a withdrawal syndrome with increased frequency of angina and even precipitation of myocardial infarction.
Acebutolol
Hydrastine
Tolbutamide
Prazosin
Phenylephrine
Telmisartan
Sildenafil
Metergoline